Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients.

Abstract

Heterotopic ossification occurring after the use of commercially available bone morphogenetic proteins has not been widely reported. We describe four cases of heterotopic ossification in patients treated with either recombinant bone morphogenetic protein 2 or recombinant bone morphogenetic protein 7. We found that while some patients were asymptomatic, heterotopic ossification which had occurred around a joint often required operative excision with good results.

• Authors: T W Axelrad, B Steen, D W Lowenberg, W R Creevy, T A Einhorn
• Journal: The Journal of bone and joint surgery. British volume (J Bone Joint Surg Br) Vol. 90 Issue 12 Pg. 1617-22 (Dec 2008) ISSN: 2044-5377 [Electronic] England
• PMID: 19043134 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bone Morphogenetic Protein 2
• Bone Morphogenetic Protein 7
• Bone Morphogenetic Proteins
• Recombinant Proteins
• Transforming Growth Factor beta
• recombinant human bone morphogenetic protein-2
• Bone Morphogenetic Protein Receptors

Topics

• Adult
• Bone Matrix (surgery)
• Bone Morphogenetic Protein 2
• Bone Morphogenetic Protein 7 (adverse effects)
• Bone Morphogenetic Protein Receptors (metabolism)
• Bone Morphogenetic Proteins (adverse effects)
• Female
• Humans
• Humeral Fractures (diagnostic imaging, therapy)
• Male
• Middle Aged
• Ossification, Heterotopic (diagnostic imaging, etiology, surgery)
• Postoperative Complications (etiology, surgery)
• Radiography
• Recombinant Proteins (adverse effects)
• Transforming Growth Factor beta (adverse effects)
• Treatment Outcome